Labcorp entered Q3 2026 earnings with its share price already on an upswing, then the stock jumped another 8.8% to close at US$360.25 after the release. That kind of one day move implies a big surprise. The actual story is tighter and more focused. Revenue reached US$3.8b and adjusted earnings per share came in at US$4.78, with free cash flow reported at US$412m. The real hinge for this quarter is margin strength in Diagnostics and Biopharma Laboratory Services, which is what the market appears to be rewarding so aggressively today.
Like the margin strength in Labcorp Holdings but want a broader set of cash-generative operators to compare it with? Take a look at our screener of list of solid balance sheet and fundamentals stocks (24 results)
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$3,810m vs. US$3,563.5m (up 6.9%)
- Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$262.8m vs. US$261.1m (up 0.7%)
- Basic EPS (Q3 2026 vs. Q3 2025): US$3.24 vs. US$3.14 (up 3.1%)
- Adjusted Operating Margin (Q3 2026 vs. Q3 2025): 15.0% vs. 14.4% (up 60 bps)
Earnings grab attention, but investors who care about what a business is worth usually track the cash moving through the system rather than just what shows up in quarterly profit figures. On Labcorp Holdings' latest numbers, if you focus on cash generation and apply a discounted cash flow lens, the stock could be a narrow 15% undervalued.
Labcorp specialty testing thesis meets key execution checks
The bullish story centers on Labcorp turning specialty and biopharma work into a higher quality earnings engine.
"Labcorp Holdings continues to expand higher value specialty testing in oncology, neurology, autoimmune disease and women’s health, with this franchise now around US$2b in diagnostics revenue and a rising share of esoteric and specialty work, which supports higher revenue per patient encounter and contribution to earnings."
Q3 results align with that script. Diagnostics revenue reached US$2.9b with organic growth led by specialty assays that are growing about 3x the broader market. Esoteric testing rose from 38% to 42% of diagnostic revenue since early 2024, and segment margin moved to 16.7%. That mix shift, together with 60 bps of enterprise margin expansion and raised 2026 EPS guidance, indicates milestones achieved on this higher value focus.
Reimbursement and execution risks still shadow Labcorp’s outlook
The bear side questions whether external pressure and execution risk will erode that progress.
"The potential financial implications of PAMA cuts remain a live risk and management now quantifies this at about a US$100 million annual impact to both revenue and operating income in the first year, which could reduce net margins and earnings if the legislation proceeds without delay or change."
Recent numbers do not reflect that hit yet. Revenue grew 6.9%, Biopharma Laboratory Services margin reached 18.3%, and free cash flow came in at US$412m. Management raised both revenue and EPS guidance and reaffirmed 2026 to 2029 targets, while warning that proposed PAMA cuts from 2027 of about US$125m will need to be offset by LaunchPad savings and M&A synergy rather than organic growth alone.
One Narrative disagrees with today's price. → See where this Narrative says Labcorp Holdings should trade.
Hunt For The Next Setup
Labcorp Holdings just showed how quickly sentiment can swing when a margin story lands cleanly. The real opportunity sits in spotting stocks that could be undervalued before the market closes the gap.
- Company 1 - 32% below our estimate - sells a compute platform hyperscale customers use as generative models outgrow traditional server architectures.
- Company 2 - 23% below our estimate - expands a robotic surgery ecosystem hospitals use to shift joint procedures into higher acuity, data-rich theatres.
- Company 3 - 46% below our estimate - wins large public infrastructure projects that convert a deep backlog into multi-year construction and project management fees.
Three companies from the same screener. Open every one of the 29 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com